Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA releases stunning first images of Earth taken by the Artemis II astronauts - 2When does Spotify Wrapped come out? The music streamer says 'soon.'
- 310 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- 4Meet the astronauts about to make history on flight around the moon
- 5Virtual reality opens doors for older people to build closer connections in real life
- Surge of off‑lease electric vehicles expected to drive down used EV prices
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- The Craft of Computerized Detox: Individual Trials
- Quandoo to shut restaurant booking platform by end of 2026
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- Find Serenity: 10 Stunning Setting up camp Areas
- Going with Children: Tips for Tranquil Family Get-aways
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Tens of thousands protest as far-right AfD forms new youth group
